Brii Bio Completes $155 Million Financing for Anti-infective/CNS Drugs

Brii Biosciences, a Shanghai-US company developing anti-infectives and CNS products for China , completed a $155 million Series C financing. Brii develops its own anti-infective candidates for drug-resistant and otherwise difficult-to-treat pathogens. and it in-licenses other programs. Over the past year, several reports have surfaced that Brii is planning a Hong Kong IPO. The C round was led by Invesco Developing Markets Fund with additional funding from GIC and an unnamed global fund. More details... Share this with colleagues: // //